BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. Source
No articles found.
Neurotrope is a clinical-stage biotech company leveraging Bryostatin-1 and its ana...
Neurotrope is a clinical-stage biotech company ...
Quidel Corporation (Nasdaq: QDEL) is a California-based leading manufacturer of di...
Quidel Corporation (Nasdaq: QDEL) is a Californ...
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on ...
Alder BioPharmaceuticals is a clinical-stage bi...
Forward Pharma A/S is a Danish biopharmaceutical company that commenced developmen...
Forward Pharma A/S is a Danish biopharmaceutica...
Neurocrine Biosciences (Nasdaq: NBIX) is a neuroscience-focused, biopharmaceutical...
Neurocrine Biosciences (Nasdaq: NBIX) is a neur...
We are a biotechnology company focused on delivering transformational therapies fo...
We are a biotechnology company focused on deliv...
We are a biotechnology company developing novel immunotherapy treatments for cance...
We are a biotechnology company developing novel...
Join the National Investor Network and get the latest information with your interests in mind.